Literature DB >> 26281537

[Advances in studies on pharmacological action of main chemical constituent of Curcuma Zedoary in preventing in-stent restenosis].

Yuan-yuan Cui, Jian-gang Liu, Fu-hai Zhao, Da-zhuo Shi.   

Abstract

Traditional Chinese medicine Curcuma Zedoary ( E'Zhu) contains essential oil, curcuminoid and other effective constituents, with such pharmacological actions as anti-platelet aggregation, lowing blood lipid, anti-oxidation and anti-inflammation. In recent years, studies have showed that certain extracts and chemical components of E'Zhu could mitigate myocardial cell mitochondria injury and protect vascular endothelium by enhancing heme oxygenase-1 activity, inhibit nuclear factor NF-kappaB, target genes interleukin-associated kinase-1 (IRAK-1), tumor necrosis factor receptor-6 (TRAF-6) and vascular cell adhesion molecule-1 (VCAM-1), reduce inflammatory infiltration, and inhibit growth factor-induced smooth muscle cells (SMCs) proliferation and migration by impacting oxidation of cellular phosphatases. Due to its different functions in vascular endothelial cells and smooth muscle cells, E'Zhu has been applied in drug-eluting stents, with a potential effect in preventing in-stent restenosis and thrombogenesis. In this paper, studies on pharmacological effects and mechanisms of extracts and main chemical constituents from E'Zhu in preventing vascular restenosis were summarized.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26281537

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  3 in total

1.  Efficacy and Safety of Shenqisuxin Granule for Non-ST-segment Elevation Acute Coronary Syndrome: Study Protocol for a Randomized, Double-Blinded, Placebo-Controlled Trial.

Authors:  Xiaoping Wu; Ming Guo; Shihua Shi; Shengnan Shi; Yanping Deng; Shenglan Wang; Yabing Wang; Peili Wang; Keji Chen
Journal:  Front Cardiovasc Med       Date:  2022-06-09

2.  Safety and Efficacy of the C-117 Formula for Vulnerable Carotid Artery Plaques (Spchim): A Randomized Double-Blind Controlled Pilot Study.

Authors:  Baoying Gong; Xiuyan Chen; Rongming Lin; Feng Zhang; Jingxin Zhong; Qixin Zhang; Yuexiang Zhou; Haijun Li; Liling Zeng; Zonghua Jiang; Jianwen Guo
Journal:  Evid Based Complement Alternat Med       Date:  2019-07-17       Impact factor: 2.629

3.  A multi-center, randomized, double-blinded, parallel, placebo-controlled study to assess the efficacy and safety of Shenqisuxin granule in complex coronary artery disease after PCI: Study protocol.

Authors:  Xiaoping Wu; Mingyu Yan; Xingxue Pang; Hui Wu; Zhigeng Hu; Rui Xiao; Jianlue Pan; Ying Li; Shengnan Shi; Yanping Deng; Jiaxi Li; Peili Wang; Keji Chen
Journal:  Front Cardiovasc Med       Date:  2022-09-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.